natgillin/translations-raw huggingface dataset:
Tavanic is contraindicated in breast-feeding women.
Zdravilo Tavanic je kontraindicirano med dojenjem.
Postmarketing serious adverse reactions, including deaths and the requirement for respiratory support, have been associated with fluoroquinolone use in patients with myasthenia gravis.
V obdobju po prihodu zdravila na trg je bila uporaba fluorokinolonov pri bolnikih z miastenijo gravis povezana z resnimi neželenimi učinki, vključno s smrtjo in potrebo po dihalni podpori.
PVC/ALUMINIUM FOIL / BLISTER
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU PVC/ ALUMINIJSKA FOLIJA/ PRETISNI OMOT
The pharmacokinetics of levofloxacin are affected by renal impairment.
Okvara ledvic vpliva na farmakokinetiko levofloksacina.
Pack sizes for 250 mg tablets: 1, 3, 5, 7, 10, 50 and 200 as commercially available.
Velikost pakiranja 250 mg tablet: 1, 3, 5, 7, 10, 50 in 200 tablet.
NAME OF THE MARKETING AUTHORISATION HOLDER [To be completed nationally]
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM [izpolni država članica]
Tinnitus
Astenija
Pack sizes for 500 mg tablets: 1, 5, 7, 10, 50, 200 and 500 as commercially available.
Velikost pakiranja 500 mg tablet: 1, 5, 7, 10, 50, 200 in 500 tablet Na trgu morda ni vseh navedenih pakiranj.
Acinetobacter baumannii Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Klebsiella pneumoniae Morganella morganii Proteus mirabilis Providencia stuartii Pseudomonas aeruginosa Serratia marcescens
Enterobacter aerogenes Enterobacter cloacae Escherichia coli
• Fits (convulsions)
• Pankreatitis (vnetje trebušne slinavke)
Method of administration
Postopek uporabe
What Tavanic tablets are and what they are used for The name of your medicine is Tavanic tablets.
Kaj je zdravilo Tavanic tablete in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Tavanic tablete Kako jemati zdravilo Tavanic tablete Možni neželeni učinki
How to store Tavanic tablets
Shranjevanje zdravila Tavanic tablete
The active ingredient is levofloxacin.
Zdravilna učinkovina je levofloksacin.
Pneumonia
Bolezni živčevja
Skin and subcutaneous tissue disorders b
Bolezni kože in podkožjab
• This medicine has been prescribed for you only.
- Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
Annex III
CAPD)1
Tendon disorders (see sections 4.3 and 4.4) including tendinitis (e.g. Achilles tendon) Muscular weakness which may be of special importance in patients with myasthenia gravis (see section 4.4 )
Ahilove tetive), Mišična šibkost, ki je lahko posebno pomembna pri bolnikih z miastenijo gravis (glejte poglavje
Pyrexia
• Dojite
• Keep this leaflet.
• Ne sončite se
PACKAGE LEAFLET
odmerna shema
Package leaflet: Information for the user Tavanic 250 mg tablets
NAVODILO ZA UPORABO Tavanic 250 mg tablete
BATCH NUMBER Batch
ŠTEVILKA SERIJE Lot
Diarrhoea Vomiting Nausea
Toksična epidermalna nekroliza,
Ear and Labyrinth disorders
Ušesne bolezni, vključno z motnjami labirinta
Peripheral sensory neuropathy (see section 4.4) Peripheral sensory motor neuropathy (see section 4.4) Parosmia including anosmia Dyskinesia
Periferna senzoričnomotorična nevropatija (glejte poglavje 4.4)
Sinuses infection
Žilne bolezni
Insomnia Anxiety Confusional state
Nespečnost Ansioznost Zmedenost
The expiry date refers to the last day of the month.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
Close monitoring of these patients is therefore necessary if they are prescribed levofloxacin.
Če takšni bolniki dobijo zdravilo Tavanic, jih je treba natančno nadzirati.
• General weakness
•Splošna šibkost
Further information on its orphan designations can be found here.
Več informacij o zdravilih sirotah je na voljo tukaj.
The company presented data from a main study in 327 patients with myelofibrosis that looked at the number of patients whose spleen size reduced by at least 35% after 24 weeks of treatment.
Družba je predložila podatke iz glavne študije, v kateri je sodelovalo 327 bolnikov z mielofibrozo, v njej pa so ugotavljali število bolnikov, pri katerih se je vranica po 24 tednih zdravljenja zmanjšala za vsaj 35 %.
Furthermore, the CHMP noted that more information was needed about the starting materials used in the manufacture of Enpaxiq and how it acts on certain target proteins in the body.
Nadalje je odbor CHMP poudaril, da je potrebnih več informacij o začetnih materialih, uporabljenih za izdelavo zdravila Enpaxiq, in o načinu njegovega delovanja na določene tarčne beljakovine v telesu.
The Committee had a number of concerns: the reduction in spleen size, the main measure of effectiveness in the study, appeared to be lower with Enpaxiq than with another medicine of its class, with no improvement in symptom scores; the incidence of low blood platelet levels (which can cause bleeding) was higher in patients treated with Enpaxiq; and a higher number of deaths occurred in patients taking Enpaxiq than in those receiving best available therapy, including deaths due to bleeding and effects on the heart.
Odbor je imel številne pomisleke: zmanjšanje velikosti vranice, glavno merilo učinkovitosti v študiji je bilo pri zdravilu Enpaxiq manjše kot pri drugem zdravilu istega razreda, pri čemer se ocene simptomov niso izboljšale; pojavnost nizkih ravni trombocitov (kar lahko povzroči krvavitev) je bila pri bolnikih, zdravljenih z zdravilom Enpaxiq, večja; in večje število smrti pri bolnikih, zdravljenih z zdravilom Enpaxiq, kot pri bolnikih, ki so prejemali najboljše razpoložljivo zdravljenje, vključno s smrtmi zaradi krvavitve in učinkov na srce.
Withdrawal of the marketing authorisation application for Enpaxiq (pacritinib) EMA/192276/2017
Umik vloge za pridobitev dovoljenja za promet z zdravilom Enpaxiq (pakritinib) EMA/192276/2017
The study compared Enpaxiq with ‘best available therapy', which included treatments that do not act on JAK proteins such as hydroxyurea or supportive care.
V študiji so primerjali zdravilo Enpaxiq z „najboljšim razpoložljivim zdravljenjem“, ki je vključevalo zdravila, ki ne delujejo na beljakovine JAK, kot sta hidroksisečnina ali podporno zdravljenje.
The company said that it intends to integrate the new data from the study into its current dossier before approaching EMA to discuss a new application.
Družba je navedla, da bo nove podatke iz študije vključila v trenutno dokumentacijo, preden se bo z agencijo EMA dogovarjala o novi vlogi.
On 20 February 2017, CTI BioPharma officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Enpaxiq, for treating patients with an enlarged spleen or other symptoms of myelofibrosis.
Družba CTI BioPharma je 20. februarja 2017 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za pridobitev dovoljenja za promet z zdravilom Enpaxiq, namenjenim zdravljenju bolnikov s povečano vranico ali drugimi simptomi mielofibroze.
By blocking these proteins, Enpaxiq is expected to slow down the production of immature blood cells and thereby help reduce the symptoms of the disease.
Z zaviranjem teh beljakovin naj bi zdravilo Enpaxiq upočasnilo tvorbo nezrelih krvnih celic in tako zmanjšalo simptome bolezni.
In myelofibrosis, patients have too much of these proteins, which cause the production of immature blood cells, some of which migrate to organs such as the spleen, causing them to become enlarged.
Pri mielofibrozi imajo bolniki teh beljakovin preveč, kar povzroči tvorbo nezrelih krvnih celic, od katerih nekatere potujejo v organe, kot je vranica, ki se zato povečajo.
Withdrawal of the marketing authorisation application for Enpaxiq (pacritinib)
Umik vloge za pridobitev dovoljenja za promet z zdravilom Enpaxiq (pakritinib)
Given these concerns, the Committee was of the opinion that the benefits of Enpaxiq had not been shown to outweigh its risks.
Glede na te pomisleke je Odbor menil, da koristi zdravila Enpaxiq ne odtehtajo z njim povezanih tveganj.
It was to be available as capsules to be taken by mouth.
Na voljo naj bi bilo v obliki kapsul, ki se jemljejo peroralno.
The company stated in its letter to the Agency that it was withdrawing the application because there was not enough time in the current application procedure to provide new data from a second main study with Enpaxiq.
Družba je v dopisu, s katerim je agencijo obvestila o umiku vloge, navedla, da vlogo umika, ker v okviru trenutnega postopka za odobritev vloge za dovoljenje za promet z zdravilom ni dovolj časa, da bi lahko predložili nove podatke druge glavne študije, opravljene z zdravilom Enpaxiq.
Enpaxiq is a medicine that contains the active substance pacritinib.
Enpaxiq je zdravilo, ki vsebuje zdravilno učinkovino pakritinib.
The company informed the CHMP that there are no consequences for patients currently included in clinical trials or compassionate use programmes with Enpaxiq.
Družba je odbor CHMP obvestila, da umik nima nobenih posledic za bolnike, ki trenutno sodelujejo v kliničnih preskušanjih ali programih sočutne uporabe zdravila Enpaxiq.
Enpaxiq was expected to be used to treat patients with an enlarged spleen or other symptoms of myelofibrosis - a disorder in which scar tissue builds up in the bone marrow where blood cells are produced.
Zdravilo Enpaxiq naj bi se uporabljalo za zdravljenje bolnikov s povečano vranico ali drugimi simptomi mielofibroze, tj. motnje, pri kateri se v kostnem mozgu, kjer nastajajo krvne celice, kopiči brazgotinsko tkivo.
The active substance in Enpaxiq, pacritinib, blocks the action of JAK2 and FLT3, two proteins involved in the production and growth of blood cells.
Aktivna učinkovina zdravila Enpaxiq, pakritinib, zavira delovanje beljakovin JAK2 in FLT3, ki sta vključeni v tvorbo in rast krvnih celic.
Enpaxiq was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 25 August 2010 for different types of myelofibrosis.
Zdravilo Enpaxiq je bilo 25. avgusta 2010 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni) za zdravljenje različnih vrst mielofibroze.
What was Enpaxiq expected to be used for?
Za kaj naj bi se zdravilo Enpaxiq uporabljalo?
What is Enpaxiq?
Kaj je zdravilo Enpaxiq?
At the time of the withdrawal of application, the CHMP was of the provisional opinion that Enpaxiq could not have been approved for myelofibrosis.
Odbor CHMP je ob umiku vloge začasno menil, da zdravila Enpaxiq ni mogoče odobriti za zdravljenje mielofibroze.
How does Enpaxiq work?
Kako zdravilo Enpaxiq deluje?
Further information on Mulpleo can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/mulpleo.
Nadaljnje informacije za zdravilo Mulpleo so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/mulpleo.
Similar effects occurred in patients receiving placebo.
Podobni učinki so se pojavili pri bolnikih, ki so prejemali placebo.
Mulpleo received a marketing authorisation valid throughout the EU on 18 February 2019.
Za zdravilo Mulpleo je bilo 18. februarja 2019 izdano dovoljenje za promet, veljavno po vsej EU.
What measures are being taken to ensure the safe and effective use of Mulpleo?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Mulpleo?
The European Medicines Agency decided that Mulpleo's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zaključila, da so koristi zdravila Mulpleo večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Other information about Mulpleo
Druge informacije o zdravilu Mulpleo
Treatment with Mulpleo should start at least 8 days before the procedure and the recommended dose is 1 tablet daily for 7 days.
Zdravljenje z zdravilom Mulpleo je treba začeti najmanj osem dni pred posegom, priporočeni odmerek pa je ena tableta na dan, sedem dni.
What benefits of Mulpleo have been shown in studies?
Kakšne koristi zdravila Mulpleo so se pokazale v študijah?
1 Previously known as Lusutrombopag Shionogi.
1 Prej znano pod imenom Lusutrombopag Shionogi.
As for all medicines, data on the use of Mulpleo are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Mulpleo stalno spremljajo.
What is Mulpleo and what is it used for?
Kaj je zdravilo Mulpleo in za kaj se uporablja?
Why is Mulpleo authorised in the EU?
Zakaj je bilo zdravilo Mulpleo odobreno v EU?
Mulpleo is available as 3 mg tablets.
Zdravilo Mulpleo je na voljo v obliki 3-miligramskih tablet.
An overview of Mulpleo and why it is authorised in the EU
Pregled zdravila Mulpleo in zakaj je odobreno v EU
What are the risks associated with Mulpleo?
Kakšna tveganja so povezana z zdravilom Mulpleo?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Mulpleo have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Mulpleo upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Side effects reported with Mulpleo are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Mulpleo, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Unwanted effects that occurred in studies are thought to result from patients' medical condition and the nature of the invasive procedure for which Mulpleo was used.
Neželeni učinki, ki so se pojavili v študijah, naj bi bili posledica zdravstvenega stanja bolnikov in narave invazivnega posega, pri katerem je bilo zdravilo Mulpleo uporabljeno.
Mulpleo is a medicine used to prevent excessive bleeding in adults with thrombocytopenia due to longstanding liver disease.
Mulpleo je zdravilo, ki se uporablja za preprečevanje čezmerne krvavitve pri odraslih s trombocitopenijo zaradi dolgotrajne bolezni jeter.
For more information about using Mulpleo, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Mulpleo glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
The second study involving 215 adults found that 65% of patients who took Mulpleo did not require platelet transfusion before their procedure, compared with 29% of patients who received placebo.
V drugi študiji, v katero je bilo vključenih 215 odraslih, so ugotovili, da 65 % bolnikov, ki so jemali zdravilo Mulpleo, pred posegom ni potrebovalo transfuzije trombocitov, v primerjavi z 29 % bolnikov, ki so prejemali placebo.
Unwanted effects that occurred in studies involving patients taking Mulpleo were headache, nausea (feeling sick), portal vein thrombosis (a blockage in the blood vessel that carries blood from the intestines to the liver) and rash.
Neželeni učinki, ki so se pojavili v študijah, v katere so bili vključeni bolniki, ki so prejemali zdravilo Mulpleo, so bili glavobol, navzeja (siljenje na bruhanje), tromboza portalne vene (zapora krvne žile, ki prenaša kri iz črevesja v jetra) in izpuščaj.
The active substance in Mulpleo, lusutrombopag, attaches to the same receptors as thrombopoietin, helping to increase the platelet count.
Učinkovina v zdravilu Mulpleo, lusutrombopag, se veže na iste receptorje kot trombopoetin in pomaga povečati število trombocitov.
Studies have found that Mulpleo increases platelet count, thereby lowering the risk of excessive bleeding during or after an invasive procedure and reducing the need for transfusing platelets.
V študijah se je izkazalo, da zdravilo Mulpleo poveča število trombocitov, s čimer zmanjša tveganje za čezmerno krvavitev med invazivnim posegom ali po njem ter potrebo po transfuziji trombocitov.
The first study, involving 96 adults, found that 79% of patients who took Mulpleo did not require a transfusion of platelets before their procedure, compared with 13% of patients who received placebo (a dummy treatment).
V prvi študiji, v katero je bilo vključenih 96 odraslih, so ugotovili, da 79 % bolnikov, ki so jemali zdravilo Mulpleo, pred posegom ni potrebovalo transfuzije trombocitov, v primerjavi s 13 % bolnikov, ki so prejemali placebo (zdravilo brez učinkovine).
In two main studies involving adults with low levels of platelets due to long-standing liver disease, Mulpleo increased platelet count before an invasive procedure and reduced the need for transfusions.
V dveh glavnih študijah, v kateri so bili vključeni odrasli z majhnim številom trombocitov zaradi dolgotrajne bolezni jeter, je zdravilo Mulpleo povečalo število trombocitov pred invazivnim posegom in zmanjšalo potrebo po transfuzijah.
Mulpleo contains the active substance lusutrombopag.
Zdravilo Mulpleo vsebuje učinkovino lusutrombopag.
How is Mulpleo used?
Kako se zdravilo Mulpleo uporablja?
For more information on the side effects and restrictions of Mulpleo, see the package leaflet.
Za več informacij o neželenih učinkih in omejitvah pri uporabi zdravila Mulpleo glejte navodilo za uporabo.
How does Mulpleo work?
Kako zdravilo Mulpleo deluje?
This generally takes 30 minutes.
To na splošno traja 30 minut.
You do not need to do anything about it.
Glede tega vam ni treba narediti ničesar.
Date of first authorisation: 8 January 2018
Datum prve odobritve: 8. januar 2018
Individual day and night time scores were similar.
Posamezne ocene podnevi in ponoči so bile podobne.
Long-term safety
Dolgoročna varnost
• through clothing
• skozi oblačila.
Important!
Pomembno!
Let it air dry.
Pustite, da se na zraku posuši.
Not known (the frequency cannot be determined from the available data):
Neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti):
This creates a firmer surface.
Tako boste ustvarili bolj čvrsto površino.
Elderly patients (≥65 years old)
Starejši bolniki (stari ≥ 65 let)
Such reactions may happen within hours or days after the injection.
Takšne reakcije se lahko pojavijo v nekaj urah ali dneh potem, ko ste dobili injekcijo.
Total duration of treatment: 104 - 112 weeks
Celotno trajanje zdravljenja: 104-112 tednov.
It is important that you talk to your doctor about how to recognise early symptoms of serious allergic reactions and how to manage these reactions if they occur.
Pomembno je, da se z zdravnikom pogovorite o tem, kako prepoznati zgodnje simptome resnih alergijskih reakcij in kako te reakcije obvladati, če se pojavijo.
Wash your hands well with soap and water.
Roke si dobro umijte z milom in vodo.
Children and adolescents The safety and benefits of this medicine are not known in children below the age of 18.
Otroci in mladostniki Varnost in koristi tega zdravila niso znane pri otrocih, mlajših od 18 let.
• if you have a parasitic infection or if you live in an area where parasitic infections are common or you are travelling to such a region.
• če imate kakšno okužbo s paraziti, če živite na območju, kjer so parazitske okužbe pogoste, ali potujete na takšno območje.
It may contain small white particles.
Vsebuje lahko majhne bele delce.
Results shown based on last available data for each variable.
Prikazani so rezultati na podlagi zadnjega razpoložljivega podatka za vsako posamezno spremenljivko.
There may be new information.
Vključene so namreč lahko kakšne nove informacije.
These reactions may occur within hours of administration, but in some instances have a delayed onset (i.e. days).
Te reakcije se lahko pojavijo v nekaj urah po uporabi, a v nekaterih primerih se pojavijo pozno (tj. v nekaj dneh).
No dedicated animal studies have been conducted.
Namenskih študij na živalih niso izvedli.
n= number of patients with data at timepoint.
n=število bolnikov, ki so na časovni točki imeli podatke.
Number of patients (n) varies slightly due to the number of patients for whom data were available for each variable.
Število bolnikov (n) se rahlo razlikuje zaradi števila bolnikov, za katere so bili podatki na voljo za vsako posamezno spremenljivko.
The green needle guard is now exposed.
Zeleni ščitnik igle je zdaj izpostavljen.
This should be done gradually, under the direct supervision of your doctor.
To je treba opraviti postopoma, pod neposrednim nadzorstvom zdravnika.
If the green plunger does not fill the viewing window, you may not have received the full dose.
Če zeleni bat ne napolni okenca za ogled, morda niste prejeli celotnega odmerka.
You will hear a second ‘click'.
Slišali boste drugi "klik".
However, no data are available in patients over 75 years of age.
Toda za bolnike, starejše od 75 let, podatkov ni.
Median percent reduction
Mediani odstotek zmanjšanja
Most antibodies were neutralising and persistent.
Večina protiteles je bila nevtralizirajočih in dolgotrajnih.
Hold down firmly for 15 seconds.
Držite močno pritisnjeno 15 sekund.
For each injection, choose a different site that is at least 3 cm away from where you last injected.
Za vsako injiciranje izberite drugo mesto, ki je vsaj 3 cm proč od mesta, kamor ste zdravilo injicirali zadnjič.
Its administration to pregnant women should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus.
Njegova uporaba pri nosečnicah pride v poštev le, če je pričakovana korist za mater večja od vsakega možnega tveganja za plod.
It may contain particles.
Lahko vsebuje delce.
Open the carton.
Odprite škatlo.
Risk to the breast-fed child cannot be excluded.
Tveganja za dojene otroke ni mogoče izključiti.
For examples of the associated manifestations reported and a description of the time to onset, see section 4.4.
Za primere opisanih povezanih manifestacij in opis časa do njihovega pojava glejte poglavje 4.4.
Currently available data in children 12 to less than 18 years old are described in sections 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.
Trenutno razpoložljivi podatki pri otrocih, starih od 12 do 18 let, so opisani v poglavjih 4.8, 5.1 in 5.2, vendar priporočil o odmerjanju ni mogoče dati.
You will hear a click.
Slišali boste "klik".
There are no fertility data in humans.
Podatkov o plodnosti pri človeku ni.
The second click tells you the injection has finished.
Drugi klik vam pove, da je injiciranje končano.
Go straight on to the next steps, without delay.
Brez odlašanja nadaljujte z naslednjimi koraki.
Other medicines for asthma
Druga zdravila za astmo
Do not inject:
Ne injicirajte:
The results summarised below are those for the recommended dosing regimen.
Spodaj povzeti rezultati se nanašajo na priporočeno shemo odmerjanja.
Do not use this medicine after the expiry date which is stated on the label.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki.
• the security seal on the carton has been broken
• če je varnostni pečat na škatli pretrgan,
Press down firmly.
Močno pritisnite navzdol.
This medicine may weaken your ability to fight certain types of parasitic infections,
To zdravilo namreč lahko oslabi vašo zmožnost za premagovanje določenih vrst okužb s paraziti.
This is to make sure you inject all of the medication.
Tako se boste prepričali, da ste injicirali vse zdravilo.
Check the viewing window to make sure all the liquid has been injected.
Preverite okence za ogled in se tako prepričajte, da je bila injicirana vsa tekočina.
• If you are allergic to benralizumab or any of the other ingredients of this medicine (listed in section 6).
• če ste alergični na benralizumab ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
The IL-5 receptor is specifically expressed on the surface of eosinophils and basophils.
Receptor IL-5 je specifično izražen na površini eozinofilcev in bazofilcev.
• fever (high temperature)
• zvišana telesna temperatura (vročina)
• into scars or damaged skin
• v brazgotine ali poškodovano kožo,
This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
Te informacije niso nadomestilo za pogovor z zdravnikom o vaši bolezni in vašem zdravljenju.
Following subcutaneous administration, the elimination half-life was approximately 15.5 days.
Po subkutani uporabi je bil razpolovni čas izločanja približno 15,5 dni.
Keep pushing until it is down as far as it will go.
Potiskajte navzdol, dokler gre.